12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oritavancin: Phase III data

In patients with microbiologically-confirmed methicillin-resistant Staphylococcus aureus (MRSA) infection (n=201), 82% of patients receiving oritavancin achieved an early clinical response vs. 81.2% for vancomycin. Additionally, the proportion of patients in the subgroup with a >20% reduction in lesion area at 48-72 hours was 96% in the oritavancin arm vs. 90.1% in the vancomycin arm. Furthermore, 84% of patients in the oritavancin arm achieved investigator-assessed clinical cure vs. 85.1% for vancomycin. The proportion of patients who experienced >=1 adverse event was similar between treatment groups (50.9% vs. 50.2%).

Last December, the company reported data from the identical Phase III SOLO I trial in 968 patients...

Read the full 502 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >